Sonata Therapeutics Partners with Champalimaud Foundation to Develop SNT-3012 for the Treatment of Pancreatic and Colorectal Cancers
Shots:
- Sonata Therapeutics and the Champalimaud Foundation have entered into a research collaboration to develop the former’s SNT-3012 to treat pancreatic and colorectal cancers
- The partnership will leverage Sonata's knowledge of Network Medicines and the Champalimaud Foundation's patient-derived samples along with its scientific & clinical expertise to commence PoC studies for the clinical development of SNT-3012
- SNT-3012, the company’s Network Medicines, coordinated all the key cell types of the cancers and induced immune-mediated tumor rejection that resulted in tumor regression in both warm & cold syngeneic tumor models
Ref: Sonata Therapeutics | Image: Sonata Therapeutics
Related News:- 23andMe's MAP Report Receives FDA's 510(k) Clearance for Hereditary Colorectal Cancers
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
